About Bal Pharma Limited
Data last updated: 14 July 2026
Bal Pharma Limited is a public limited company based in Bangalore South, Karnataka, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 19 May 1987, the company has been in operation for over 39 years.
Registered with ROC Bangalore under CIN L85110KA1987PLC008368. Listed on BSE: 524824 and NSE: BALPHARMA.
Capital: an authorised share capital of ₹24.5 Cr and a paid-up capital of ₹15.92 Cr. It is led by directors including Jatish Sheth and Nicola Neeladri.
Last AGM: 25 September 2025. Financial statements filed for year ended 31 March 2025. Office: Bangalore South, Karnataka.
As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹311.66 Cr, a growth of 2.83% compared to the previous year. The net worth stands at ₹82.25 Cr (up 6.26% YoY). Total assets are valued at ₹375.54 Cr (up 11.87% YoY).
The company has a workforce of approximately 715 employees as per the latest available data. Its group structure includes 4 subsidiaries.
The company is associated with 1 brand - Bal Pharma. As per MCA filings, the company has open charges of ₹234.22 Cr and satisfied charges of ₹198.12 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website balpharma.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social Media
-
Registered Address21 – 22 Bommasandra, Industrial Area, Bangalore South, Karnataka, India – 560099
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Bal Pharma Limited
Bal Pharma Limited operates one associated brand: Bal Pharma. These brands represent Bal Pharma Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of pharmaceutical APIs, formulations, and Ayurvedic products | balpharma.com |
Business Activity of Bal Pharma Limited
Bal Pharma Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Bal Pharma Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Bal Pharma Limited
Bal Pharma Limited is audited by SSJNB & CO (ICAI peer reviewed, certificate valid till 2029-03-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| SSJNB & CO (ICAI peer reviewed, certificate valid till 2029-03-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Bal Pharma Limited
Bal Pharma Limited is currently managed by 6 directors, with 20 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Jatish Sheth
Also directs:
Meganza Pharma Llp, Srushti Pharmaceuticals Private Limited
|
Director | 28 Dec 2020 | 5 Years 7 Months | Current |
| Nicola Neeladri | Director | 23 May 2020 | 6 Years 2 Months | Current |
|
Shailesh Siroya
Also directs:
Balance Clinics Llp, Lifezen Healthcare Private Limited, Kaunshya Investments Private Limited and 2 more
|
Managing Director | 01 Aug 2004 | 22 Years 0 Months | Current |
| Virupakshaya Himesh | Whole-Time Director | 28 Sep 2019 | 6 Years 10 Months | Current |
| Bheekamchand Mukesh | Additional Director | 13 Nov 2025 | 0 Years 8 Months | Current |
|
Ravindrakumar Kothari
Also directs:
Balance Clinics Llp, Lifezen Healthcare Private Limited, Aurum Research & Analytical Solutions Private Limited and 1 more
|
Director | 05 May 2025 | 1 Years 3 Months | Current |
Financials of Bal Pharma Limited FY 2026 filings available
Bal Pharma Limited reported revenue of ₹311.66 Cr (up 2.83% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹311.66 Cr | ₹303.08 Cr | ₹339.22 Cr | ₹304.22 Cr | ₹281.21 Cr | ₹250.53 Cr | ₹171.09 Cr |
| Other Income | ₹1.93 Cr | ₹2.2 Cr | ₹2.85 Cr | ₹94.06 Lakh | ₹5.15 Cr | ₹1.14 Cr | ₹1.84 Cr |
| Total Income | ₹313.59 Cr | ₹305.29 Cr | ₹342.07 Cr | ₹305.16 Cr | ₹286.37 Cr | ₹251.67 Cr | ₹172.93 Cr |
| Cost of Materials Consumed | ₹160.97 Cr | ₹149.89 Cr | ₹181.58 Cr | ₹179.19 Cr | ₹163.99 Cr | ₹135.47 Cr | ₹72.2 Cr |
| Purchases of Stock-in-Trade | ₹9.23 Cr | ₹15.06 Cr | ₹11.24 Cr | ₹11.45 Cr | ₹8.43 Cr | ₹10.43 Cr | ₹8.54 Cr |
| Changes in Inventories | -₹12.23 Cr | -₹7.05 Cr | -₹1.06 Cr | -₹17.87 Cr | -₹4.89 Cr | ₹5.05 Cr | ₹3.38 Cr |
| Employee Benefit Expense | ₹66.46 Cr | ₹62.4 Cr | ₹60.38 Cr | ₹55.3 Cr | ₹47.25 Cr | ₹41.88 Cr | ₹50.43 Cr |
| Finance Costs | ₹16.82 Cr | ₹16.85 Cr | ₹15.26 Cr | ₹12.19 Cr | ₹10.41 Cr | ₹11.97 Cr | ₹12.45 Cr |
| Depreciation & Amortisation | ₹11.08 Cr | ₹9.77 Cr | ₹10.07 Cr | ₹9.13 Cr | ₹9.04 Cr | ₹9.52 Cr | ₹7.68 Cr |
| Other Expenses | ₹55.33 Cr | ₹53.23 Cr | ₹55.56 Cr | ₹51.03 Cr | ₹42.96 Cr | ₹33.25 Cr | ₹31.78 Cr |
| Total Expenses | ₹307.65 Cr | ₹300.15 Cr | ₹333.02 Cr | ₹300.41 Cr | ₹277.18 Cr | ₹247.56 Cr | ₹186.46 Cr |
| Profit Before Exceptional Items & Tax | ₹5.94 Cr | ₹5.14 Cr | ₹9.05 Cr | ₹4.75 Cr | ₹9.18 Cr | ₹4.1 Cr | -₹13.53 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹5.94 Cr | ₹5.14 Cr | ₹9.05 Cr | ₹4.75 Cr | ₹9.18 Cr | ₹4.1 Cr | -₹13.53 Cr |
| Total Tax Expense | -₹38.62 Lakh | -₹2.1 Cr | ₹1.6 Cr | ₹2.13 Cr | ₹3.48 Cr | -₹60.96 Lakh | -₹63.76 Lakh |
| Net Profit | ₹6.32 Cr | ₹7.2 Cr | ₹7.45 Cr | ₹2.62 Cr | ₹5.7 Cr | ₹4.71 Cr | -₹12.89 Cr |
| attributable to Owners | ₹6.28 Cr | ₹7.22 Cr | ₹7.39 Cr | ₹0 | ₹5.61 Cr | ₹4.74 Cr | ₹0 |
| attributable to NCI | ₹3.65 Lakh | ₹2.13 Lakh | ₹5.35 Lakh | ₹0 | ₹9.34 Lakh | -₹3.02 Lakh | ₹0 |
| Other Comprehensive Income | ₹43.85 Lakh | ₹0 | ₹36.08 Lakh | ₹0 | ₹31,000 | ₹20.42 Lakh | -₹29.02 Lakh |
| Total Comprehensive Income | ₹6.76 Cr | ₹7.2 Cr | ₹7.81 Cr | ₹2.62 Cr | ₹5.71 Cr | ₹4.92 Cr | -₹13.18 Cr |
| EBITDA (computed) | ₹33.83 Cr | ₹31.76 Cr | ₹34.38 Cr | ₹26.06 Cr | ₹28.63 Cr | ₹25.6 Cr | ₹6.6 Cr |
| Basic EPS | ₹3.95 | ₹4.56 | ₹4.94 | ₹1.67 | ₹3.79 | ₹3.34 | ₹-8.62 |
| Diluted EPS | ₹3.95 | ₹4.56 | ₹4.96 | ₹1.68 | ₹3.71 | ₹3.34 | ₹-8.62 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹375.54 Cr | ₹335.69 Cr | ₹320.39 Cr | ₹313.17 Cr |
| Non-current Assets | ₹113.31 Cr | ₹100.82 Cr | ₹85.38 Cr | ₹85.02 Cr |
| Current Assets | ₹262.23 Cr | ₹234.87 Cr | ₹235.01 Cr | ₹228.16 Cr |
| Property, Plant & Equipment | ₹76.75 Cr | ₹70.99 Cr | ₹61.61 Cr | ₹62.18 Cr |
| Inventories | ₹116.36 Cr | ₹103.02 Cr | ₹87.81 Cr | ₹98.01 Cr |
| Trade Receivables | ₹93.63 Cr | ₹92.44 Cr | ₹99.62 Cr | ₹93.98 Cr |
| Cash & Equivalents | ₹2.3 Cr | ₹1.75 Cr | ₹4.2 Cr | ₹1.49 Cr |
| Equity (Net Worth) | ₹82.25 Cr | ₹77.4 Cr | ₹69.26 Cr | ₹63.7 Cr |
| Equity Share Capital | ₹15.92 Cr | ₹15.92 Cr | ₹15.8 Cr | ₹15.69 Cr |
| Borrowings (Non-current) | ₹31.88 Cr | ₹31.41 Cr | ₹36.38 Cr | ₹30.52 Cr |
| Borrowings (Current) | ₹127.63 Cr | ₹119 Cr | ₹103.27 Cr | ₹100.48 Cr |
| Total Debt (computed) | ₹159.52 Cr | ₹150.41 Cr | ₹139.65 Cr | ₹131 Cr |
| Current Liabilities | ₹249.23 Cr | ₹219.5 Cr | ₹203.91 Cr | ₹209.33 Cr |
| Total Liabilities | ₹293.29 Cr | ₹258.29 Cr | ₹251.13 Cr | ₹249.47 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹7.87 Cr | ₹20.74 Cr | ₹329.19 Cr | ₹23.02 Cr | ₹32.05 Cr |
| Investing Cash Flow | -₹9.85 Cr | -₹18.13 Cr | ₹0 | ₹18.43 Cr | ₹11.34 Cr |
| Financing Cash Flow | -₹27.32 Cr | ₹29.24 Lakh | ₹34.58 Cr | ₹0 | ₹1.11 Cr |
| Capital Expenditure | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Free Cash Flow (computed) | ₹7.87 Cr | ₹20.74 Cr | ₹329.19 Cr | ₹23.02 Cr | ₹32.05 Cr |
| Dividends Paid | ₹1.95 Lakh | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹29.31 Cr | ₹2.9 Cr | ₹363.78 Cr | ₹41.45 Cr | ₹44.5 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹84.08 Cr | ₹87.69 Cr | ₹74.02 Cr | ₹65.87 Cr | ₹81.88 Cr | ₹73.15 Cr | ₹73.69 Cr | ₹74.36 Cr | ₹94.63 Cr | ₹81.66 Cr | ₹92.54 Cr | ₹70.39 Cr |
| Other Income | -₹23.65 Lakh | ₹32.62 Lakh | ₹1.12 Cr | ₹72.22 Lakh | ₹1.08 Cr | ₹50.64 Lakh | -₹20.49 Lakh | ₹81.84 Lakh | ₹2.45 Cr | ₹9.53 Lakh | ₹14.21 Lakh | ₹15.67 Lakh |
| Total Income | ₹83.84 Cr | ₹88.02 Cr | ₹75.14 Cr | ₹66.59 Cr | ₹82.96 Cr | ₹73.66 Cr | ₹73.49 Cr | ₹75.18 Cr | ₹97.08 Cr | ₹81.76 Cr | ₹92.68 Cr | ₹70.54 Cr |
| Cost of Materials Consumed | ₹41.14 Cr | ₹43.51 Cr | ₹40.29 Cr | ₹36.03 Cr | ₹38.7 Cr | ₹37.58 Cr | ₹37.29 Cr | ₹36.31 Cr | ₹51.9 Cr | ₹37.91 Cr | ₹50.22 Cr | ₹41.55 Cr |
| Purchases of Stock-in-Trade | ₹1.42 Cr | ₹2.04 Cr | ₹1.78 Cr | ₹3.98 Cr | ₹6.97 Cr | ₹3.54 Cr | ₹1.4 Cr | ₹3.14 Cr | ₹4.75 Cr | ₹1.72 Cr | ₹3.26 Cr | ₹1.52 Cr |
| Changes in Inventories | -₹4.23 Cr | ₹60.63 Lakh | -₹2.14 Cr | -₹6.47 Cr | -₹1.7 Cr | -₹4.27 Cr | -₹70.34 Lakh | -₹37.53 Lakh | -₹2.88 Cr | ₹6.22 Cr | -₹16.11 Lakh | -₹4.24 Cr |
| Employee Benefit Expense | ₹18.07 Cr | ₹17.32 Cr | ₹16.27 Cr | ₹14.8 Cr | ₹15.49 Cr | ₹15.98 Cr | ₹16.02 Cr | ₹14.91 Cr | ₹15.64 Cr | ₹15.26 Cr | ₹15.3 Cr | ₹14.19 Cr |
| Finance Costs | ₹4.06 Cr | ₹4.85 Cr | ₹3.86 Cr | ₹4.05 Cr | ₹3.95 Cr | ₹5.01 Cr | ₹3.65 Cr | ₹4.24 Cr | ₹4.14 Cr | ₹3.66 Cr | ₹3.82 Cr | ₹3.64 Cr |
| Depreciation & Amortisation | ₹3.06 Cr | ₹3.23 Cr | ₹2.27 Cr | ₹2.52 Cr | ₹2.18 Cr | ₹2.69 Cr | ₹2.48 Cr | ₹2.43 Cr | ₹2.16 Cr | ₹2.96 Cr | ₹2.42 Cr | ₹2.53 Cr |
| Other Expenses | ₹17.12 Cr | ₹14.66 Cr | ₹12.09 Cr | ₹11.46 Cr | ₹14.77 Cr | ₹12.57 Cr | ₹11.98 Cr | ₹13.91 Cr | ₹15.63 Cr | ₹12.76 Cr | ₹16.23 Cr | ₹10.93 Cr |
| Total Expenses | ₹80.62 Cr | ₹86.23 Cr | ₹74.42 Cr | ₹66.38 Cr | ₹80.37 Cr | ₹73.09 Cr | ₹72.13 Cr | ₹74.56 Cr | ₹91.33 Cr | ₹80.49 Cr | ₹91.09 Cr | ₹70.11 Cr |
| Profit Before Exceptional Items & Tax | ₹3.22 Cr | ₹1.79 Cr | ₹71.73 Lakh | ₹20.85 Lakh | ₹2.59 Cr | ₹56.63 Lakh | ₹1.36 Cr | ₹61.75 Lakh | ₹5.75 Cr | ₹1.27 Cr | ₹1.6 Cr | ₹43.06 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹3.22 Cr | ₹1.79 Cr | ₹71.73 Lakh | ₹20.85 Lakh | ₹2.59 Cr | ₹56.63 Lakh | ₹1.36 Cr | ₹61.75 Lakh | ₹5.75 Cr | ₹1.27 Cr | ₹1.6 Cr | ₹43.06 Lakh |
| Total Tax Expense | -₹38.62 Lakh | ₹0 | ₹0 | ₹0 | -₹2.83 Cr | ₹4.84 Lakh | ₹31.94 Lakh | ₹35.8 Lakh | ₹21.89 Lakh | ₹41.69 Lakh | ₹62.99 Lakh | ₹33.59 Lakh |
| Net Profit | ₹3.6 Cr | ₹1.79 Cr | ₹71.73 Lakh | ₹20.85 Lakh | ₹5.38 Cr | ₹51.79 Lakh | ₹1.04 Cr | ₹25.95 Lakh | ₹5.53 Cr | ₹84.92 Lakh | ₹96.94 Lakh | ₹9.47 Lakh |
| attributable to Owners | ₹3.59 Cr | ₹1.78 Cr | ₹70.95 Lakh | - | ₹6.73 Cr | ₹48.12 Lakh | ₹1.04 Cr | ₹25.91 Lakh | ₹5.47 Cr | ₹88.89 Lakh | ₹94.57 Lakh | ₹8.43 Lakh |
| attributable to NCI | ₹1.02 Lakh | ₹1.07 Lakh | ₹77,000 | - | -₹1.53 Lakh | ₹3.67 Lakh | ₹11,000 | ₹3,000 | ₹5.91 Lakh | -₹3.97 Lakh | ₹2.37 Lakh | ₹1.05 Lakh |
| Other Comprehensive Income | ₹43.85 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹36.08 Lakh | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹4.04 Cr | ₹1.79 Cr | ₹71.73 Lakh | ₹20.85 Lakh | ₹5.38 Cr | ₹51.79 Lakh | ₹1.04 Cr | ₹25.95 Lakh | ₹5.89 Cr | ₹84.92 Lakh | ₹96.94 Lakh | ₹9.47 Lakh |
| EBITDA (computed) | ₹10.33 Cr | ₹9.87 Cr | ₹6.85 Cr | ₹6.78 Cr | ₹8.72 Cr | ₹8.26 Cr | ₹7.49 Cr | ₹7.28 Cr | ₹12.05 Cr | ₹7.89 Cr | ₹7.84 Cr | ₹6.6 Cr |
| Basic EPS | ₹2.26 | ₹1.12 | ₹0.45 | ₹0.13 | ₹3.40 | ₹0.33 | ₹0.65 | ₹0.16 | ₹3.73 | ₹0.54 | ₹0.62 | ₹0.06 |
| Diluted EPS | ₹2.26 | ₹1.12 | ₹0.45 | ₹0.13 | ₹3.40 | ₹0.33 | ₹0.65 | ₹0.16 | ₹3.74 | ₹0.54 | ₹0.62 | ₹0.06 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹310.8 Cr | ₹302.5 Cr | ₹338.54 Cr | ₹303.1 Cr | ₹280.37 Cr | ₹249.31 Cr | ₹170.67 Cr |
| Other Income | ₹2 Cr | ₹2.15 Cr | ₹3.35 Cr | ₹2.15 Cr | ₹6.49 Cr | ₹2.7 Cr | ₹3.62 Cr |
| Total Income | ₹312.8 Cr | ₹304.65 Cr | ₹341.89 Cr | ₹305.25 Cr | ₹286.86 Cr | ₹252.01 Cr | ₹174.29 Cr |
| Cost of Materials Consumed | ₹160.97 Cr | ₹149.89 Cr | ₹181.57 Cr | ₹176.45 Cr | ₹162.95 Cr | ₹135.47 Cr | ₹79.44 Cr |
| Purchases of Stock-in-Trade | ₹9.13 Cr | ₹14.97 Cr | ₹11.23 Cr | ₹11.39 Cr | ₹8.4 Cr | ₹9.98 Cr | ₹8.7 Cr |
| Changes in Inventories | -₹12.25 Cr | -₹7.08 Cr | -₹1.06 Cr | -₹17.9 Cr | -₹4.85 Cr | ₹5.13 Cr | -₹3.43 Cr |
| Employee Benefit Expense | ₹65.92 Cr | ₹61.83 Cr | ₹56.11 Cr | ₹51.91 Cr | ₹44.46 Cr | ₹39.62 Cr | ₹48.77 Cr |
| Finance Costs | ₹16.81 Cr | ₹16.85 Cr | ₹15.24 Cr | ₹12.16 Cr | ₹10.4 Cr | ₹11.96 Cr | ₹12.42 Cr |
| Depreciation & Amortisation | ₹11.06 Cr | ₹9.65 Cr | ₹8.45 Cr | ₹7.48 Cr | ₹7.24 Cr | ₹7.26 Cr | ₹7.03 Cr |
| Other Expenses | ₹54.79 Cr | ₹52.82 Cr | ₹58.25 Cr | ₹55.22 Cr | ₹46.21 Cr | ₹32.79 Cr | ₹30.93 Cr |
| Total Expenses | ₹306.43 Cr | ₹298.91 Cr | ₹329.79 Cr | ₹296.7 Cr | ₹274.8 Cr | ₹242.2 Cr | ₹183.86 Cr |
| Profit Before Exceptional Items & Tax | ₹6.37 Cr | ₹5.73 Cr | ₹12.11 Cr | ₹8.55 Cr | ₹12.06 Cr | ₹9.8 Cr | -₹9.57 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹6.37 Cr | ₹5.73 Cr | ₹12.11 Cr | ₹8.55 Cr | ₹12.06 Cr | ₹9.8 Cr | -₹9.57 Cr |
| Total Tax Expense | -₹38.61 Lakh | -₹2.07 Cr | ₹1.83 Cr | ₹2.42 Cr | ₹3.48 Cr | ₹69.93 Lakh | -₹4.17 Lakh |
| Net Profit | ₹6.75 Cr | ₹7.8 Cr | ₹10.27 Cr | ₹6.13 Cr | ₹8.57 Cr | ₹9.1 Cr | -₹9.53 Cr |
| attributable to Owners | - | - | - | - | - | - | ₹0 |
| attributable to NCI | - | - | - | - | - | - | ₹0 |
| Other Comprehensive Income | ₹43.38 Lakh | -₹4.32 Lakh | ₹35.37 Lakh | ₹22.63 Lakh | -₹60,000 | ₹8.85 Lakh | -₹30.42 Lakh |
| Total Comprehensive Income | ₹7.19 Cr | ₹7.76 Cr | ₹10.63 Cr | ₹6.35 Cr | ₹8.57 Cr | ₹9.19 Cr | -₹9.83 Cr |
| EBITDA (computed) | ₹34.23 Cr | ₹32.23 Cr | ₹35.79 Cr | ₹28.19 Cr | ₹29.69 Cr | ₹29.02 Cr | ₹9.87 Cr |
| Basic EPS | ₹4.27 | ₹4.89 | ₹6.72 | ₹3.90 | ₹5.79 | ₹6.41 | ₹-6.72 |
| Diluted EPS | ₹4.27 | ₹4.89 | ₹6.75 | ₹3.94 | ₹5.67 | ₹6.41 | ₹-6.72 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹391.06 Cr | ₹350.56 Cr | ₹361.3 Cr | ₹347.7 Cr |
| Non-current Assets | ₹115.42 Cr | ₹102.91 Cr | ₹80.16 Cr | ₹77.75 Cr |
| Current Assets | ₹275.64 Cr | ₹247.65 Cr | ₹281.14 Cr | ₹269.95 Cr |
| Property, Plant & Equipment | ₹76.73 Cr | ₹70.95 Cr | ₹53.18 Cr | ₹52.62 Cr |
| Inventories | ₹116.13 Cr | ₹102.78 Cr | ₹87.49 Cr | ₹97.69 Cr |
| Trade Receivables | ₹96.36 Cr | ₹94.85 Cr | ₹103.1 Cr | ₹94.84 Cr |
| Cash & Equivalents | ₹2.19 Cr | ₹1.64 Cr | ₹4.04 Cr | ₹1.23 Cr |
| Equity (Net Worth) | ₹104.1 Cr | ₹98.82 Cr | ₹105.58 Cr | ₹96.03 Cr |
| Equity Share Capital | ₹15.92 Cr | ₹15.92 Cr | ₹15.8 Cr | ₹15.69 Cr |
| Borrowings (Non-current) | ₹31.88 Cr | ₹31.4 Cr | ₹36.35 Cr | ₹30.52 Cr |
| Borrowings (Current) | ₹121.86 Cr | ₹113.21 Cr | ₹97.48 Cr | ₹94.71 Cr |
| Total Debt (computed) | ₹153.75 Cr | ₹144.61 Cr | ₹133.83 Cr | ₹125.23 Cr |
| Current Liabilities | ₹243.3 Cr | ₹213.46 Cr | ₹209.16 Cr | ₹212.15 Cr |
| Total Liabilities | ₹286.96 Cr | ₹251.74 Cr | ₹255.72 Cr | ₹251.67 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹8.82 Cr | ₹20.31 Cr | ₹33.35 Cr | -₹8.5 Cr | ₹18.42 Cr |
| Investing Cash Flow | -₹26.82 Cr | -₹14.9 Cr | ₹2.57 Cr | -₹17.95 Cr | ₹30.76 Cr |
| Financing Cash Flow | -₹11.76 Cr | -₹7.83 Cr | ₹24.21 Cr | ₹0 | ₹0 |
| Capital Expenditure | ₹0 | ₹18.77 Cr | -₹10.5 Cr | ₹0 | ₹0 |
| Free Cash Flow (computed) | ₹8.82 Cr | ₹1.54 Cr | ₹22.85 Cr | -₹8.5 Cr | ₹18.42 Cr |
| Dividends Paid | ₹0 | ₹1.91 Cr | ₹1.57 Cr | ₹0 | ₹0 |
| Net Change in Cash | -₹28.45 Cr | -₹2.42 Cr | ₹60.13 Cr | -₹26.45 Cr | ₹49.18 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹83.92 Cr | ₹87.49 Cr | ₹73.75 Cr | ₹65.64 Cr | ₹81.78 Cr | ₹72.89 Cr | ₹74.7 Cr | ₹73.13 Cr | ₹94.58 Cr | ₹81.49 Cr | ₹92.3 Cr | ₹70.17 Cr |
| Other Income | -₹21.82 Lakh | ₹34.51 Lakh | ₹1.13 Cr | ₹74.11 Lakh | ₹99.1 Lakh | ₹81.97 Lakh | ₹35.5 Lakh | ₹81.48 Lakh | ₹2.23 Cr | ₹25.71 Lakh | ₹41.31 Lakh | ₹44.75 Lakh |
| Total Income | ₹83.7 Cr | ₹87.84 Cr | ₹74.88 Cr | ₹66.38 Cr | ₹82.77 Cr | ₹73.7 Cr | ₹75.06 Cr | ₹73.94 Cr | ₹96.81 Cr | ₹81.75 Cr | ₹92.71 Cr | ₹70.61 Cr |
| Cost of Materials Consumed | ₹41.14 Cr | ₹43.51 Cr | ₹40.29 Cr | ₹36.03 Cr | ₹39.92 Cr | ₹37.55 Cr | ₹36.13 Cr | ₹36.31 Cr | ₹51.89 Cr | ₹37.92 Cr | ₹50.19 Cr | ₹41.57 Cr |
| Purchases of Stock-in-Trade | ₹1.44 Cr | ₹2.01 Cr | ₹1.7 Cr | ₹3.97 Cr | ₹5.67 Cr | ₹3.5 Cr | ₹2.83 Cr | ₹2.98 Cr | ₹4.76 Cr | ₹1.67 Cr | ₹3.38 Cr | ₹1.42 Cr |
| Changes in Inventories | -₹4.19 Cr | ₹61.31 Lakh | -₹2.14 Cr | -₹6.52 Cr | -₹1.64 Cr | -₹4.36 Cr | -₹73.81 Lakh | -₹34.32 Lakh | -₹2.89 Cr | ₹6.27 Cr | -₹24.52 Lakh | -₹4.2 Cr |
| Employee Benefit Expense | ₹17.92 Cr | ₹17.19 Cr | ₹16.15 Cr | ₹14.67 Cr | ₹15.35 Cr | ₹14.81 Cr | ₹14.88 Cr | ₹13.84 Cr | ₹14.56 Cr | ₹14.17 Cr | ₹14.18 Cr | ₹13.2 Cr |
| Finance Costs | ₹4.05 Cr | ₹4.85 Cr | ₹3.86 Cr | ₹4.05 Cr | ₹3.94 Cr | ₹5.01 Cr | ₹4.18 Cr | ₹3.71 Cr | ₹4.12 Cr | ₹3.66 Cr | ₹3.82 Cr | ₹3.64 Cr |
| Depreciation & Amortisation | ₹3.04 Cr | ₹3.23 Cr | ₹2.27 Cr | ₹2.52 Cr | ₹2.07 Cr | ₹2.33 Cr | ₹2.12 Cr | ₹2.08 Cr | ₹1.76 Cr | ₹2.55 Cr | ₹2.02 Cr | ₹2.12 Cr |
| Other Expenses | ₹16.99 Cr | ₹14.49 Cr | ₹11.98 Cr | ₹11.33 Cr | ₹14.66 Cr | ₹13.66 Cr | ₹14.12 Cr | ₹13.27 Cr | ₹15.94 Cr | ₹13.84 Cr | ₹17.14 Cr | ₹11.34 Cr |
| Total Expenses | ₹80.39 Cr | ₹85.89 Cr | ₹74.1 Cr | ₹66.05 Cr | ₹79.96 Cr | ₹72.5 Cr | ₹73.52 Cr | ₹71.84 Cr | ₹90.14 Cr | ₹80.08 Cr | ₹90.48 Cr | ₹69.08 Cr |
| Profit Before Exceptional Items & Tax | ₹3.31 Cr | ₹1.95 Cr | ₹78.15 Lakh | ₹32.33 Lakh | ₹2.81 Cr | ₹1.2 Cr | ₹1.53 Cr | ₹2.11 Cr | ₹6.67 Cr | ₹1.67 Cr | ₹2.23 Cr | ₹1.53 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹3.31 Cr | ₹1.95 Cr | ₹78.15 Lakh | ₹32.33 Lakh | ₹2.81 Cr | ₹1.2 Cr | ₹1.53 Cr | ₹2.11 Cr | ₹6.67 Cr | ₹1.67 Cr | ₹2.23 Cr | ₹1.53 Cr |
| Total Tax Expense | -₹38.61 Lakh | ₹0 | ₹0 | ₹0 | -₹2.79 Cr | ₹4.84 Lakh | ₹31.94 Lakh | ₹35.8 Lakh | ₹45.08 Lakh | ₹41.69 Lakh | ₹62.99 Lakh | ₹33.59 Lakh |
| Net Profit | ₹3.7 Cr | ₹1.95 Cr | ₹78.15 Lakh | ₹32.33 Lakh | ₹5.61 Cr | ₹1.16 Cr | ₹1.21 Cr | ₹1.75 Cr | ₹6.22 Cr | ₹1.26 Cr | ₹1.6 Cr | ₹1.2 Cr |
| Other Comprehensive Income | ₹43.38 Lakh | ₹0 | ₹0 | ₹0 | -₹4.32 Lakh | ₹0 | ₹0 | ₹0 | ₹35.37 Lakh | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹4.13 Cr | ₹1.95 Cr | ₹78.15 Lakh | ₹32.33 Lakh | ₹5.56 Cr | ₹1.16 Cr | ₹1.21 Cr | ₹1.75 Cr | ₹6.57 Cr | ₹1.26 Cr | ₹1.6 Cr | ₹1.2 Cr |
| EBITDA (computed) | ₹10.41 Cr | ₹10.02 Cr | ₹6.91 Cr | ₹6.89 Cr | ₹8.82 Cr | ₹8.55 Cr | ₹7.83 Cr | ₹7.89 Cr | ₹12.55 Cr | ₹7.89 Cr | ₹8.07 Cr | ₹7.29 Cr |
| Basic EPS | ₹2.60 | ₹1.22 | ₹0.49 | ₹0.20 | ₹3.51 | ₹0.73 | ₹0.76 | ₹1.11 | ₹4.16 | ₹0.80 | ₹1.02 | ₹0.76 |
| Diluted EPS | ₹2.60 | ₹1.22 | ₹0.49 | ₹0.20 | ₹3.51 | ₹0.73 | ₹0.76 | ₹1.11 | ₹4.18 | ₹0.80 | ₹1.02 | ₹0.76 |
Shareholding Pattern of Bal Pharma Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 50.86%, foreign institutional investors hold 0.14%, retail and other public shareholders hold 49.01% of Bal Pharma Limited. The company had 15,214 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 50.86% | 50.86% | 50.86% | 50.86% | 50.86% | 50.86% |
| Public | 49.14% | 49.14% | 49.14% | 49.14% | 49.14% | 49.14% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 50.86% | 50.86% | 51.23% | 51.61% | 49.57% | 44.98% | 42.45% | 42.45% | 44.57% | 44.35% | 48.83% |
| Public | 49.14% | 49.14% | 48.77% | 48.39% | 50.43% | 55.02% | 57.55% | 57.55% | 55.43% | 55.65% | 51.17% |
| Promoter change (YoY, %pts) | +0.00 | -0.37 | -0.38 | +2.04 | +4.59 | +2.53 | +0.00 | -2.12 | +0.22 | -4.48 | - |
Board & Governance of Bal Pharma Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Bal Pharma Limited has 6 directors - 3 independent and 2 executive. The board is chaired by SHAILESH SIROYA.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| SHAILESH SIROYA | Executive Director · MD · Chairperson | 1994-07-15 | 1 |
| HIMESH VIRUPAKSHYA | Executive Director | 2019-09-28 | 1 |
| RAVINDRA KUMAR KOTHARI | Non-Executive - Non Independent Director | 2025-05-05 | 1 |
| JATISH SHETH | Non-Executive - Independent Director | 2020-12-28 | 1 |
| MUKESH BHEEKAMCHAND | Non-Executive - Independent Director | 2025-11-13 | 1 |
| NICOLA NEELADI | Non-Executive - Independent Director | 2020-05-23 | 2 |
| Committee | Members |
|---|---|
| Audit Committee | JATISH SHETH (Chairperson), MUKESH BHEEKAMCHAND, NICOLA NEELADI |
| Nomination and remuneration committee | JATISH SHETH (Chairperson), MUKESH BHEEKAMCHAND, NICOLA NEELADI, RAVINDRA KUMAR KOTHARI |
| Stakeholders Relationship Committee | JATISH SHETH (Chairperson), MUKESH BHEEKAMCHAND, NICOLA NEELADI, RAVINDRA KUMAR KOTHARI, SHAILESH SIROYA |
Group Structure of Bal Pharma Limited
Bal Pharma Limited has 4 subsidiary companies. This group structure data is as of FY 2024. The corporate group structure reflects Bal Pharma Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Lifezen Healthcare Private Limited | U24230KA2014PTC077114 | - |
| Golden Drugs Private Limited | U24232KA2012PTC157474 | - |
| Aurum Research & Analytical Solutions Private Limited | U72100KA2023PTC177577 | - |
| Bal Research Foundation | U73100KA2014NPL076995 | - |
Showing major subsidiaries. Total: 4.
Charges & Borrowings of Bal Pharma Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Nov 2025 | Others | ₹4.4 Cr | Open |
| 13 Nov 2025 | Hdfc Bank Limited | ₹5 Cr | Open |
| 23 Oct 2025 | Hdfc Bank Limited | ₹24.9 Lakh | Open |
| 28 Aug 2025 | Others | ₹22 Cr | Open |
| 22 Aug 2025 | Others | ₹3 Cr | Open |
Total charge records: 41 View all charges
Employees and EPFO Compliance at Bal Pharma Limited
Bal Pharma Limited has a workforce of 715 employees as of Mar 31, 2025.
Employee and EPFO history for Bal Pharma Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Bal Pharma Limited
GST registrations and filing compliance for Bal Pharma Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Bal Pharma Limited
Credit ratings, litigation, and regulatory alerts for Bal Pharma Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Bal Pharma Limited
MSME payment history for Bal Pharma Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Bal Pharma Limited
Corporate group structure for Bal Pharma Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Bal Pharma Limited
MCA filings and documents for Bal Pharma Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Bal Pharma Limited
Recent News on Bal Pharma Limited
Frequently Asked Questions about Bal Pharma Limited
Bal Pharma Limited is an active public limited company in the pharma sector based in Bangalore South, Karnataka, India. It was incorporated on 19 May 1987 (39+ years old) and is registered under CIN L85110KA1987PLC008368. Listed on BSE: 524824 and NSE: BALPHARMA. The company has 715 employees.
Bal Pharma Limited reported revenue of ₹311.66 Cr for FY 2026 (up 2.83% YoY) based on consolidated NSE filings.
The current directors of Bal Pharma Limited are:
- Jatish Sheth - Director
- Nicola Neeladri - Director
- Shailesh Siroya - Managing Director
- Virupakshaya Himesh - Whole-Time Director
- Bheekamchand Mukesh - Additional Director
- Ravindrakumar Kothari - Director
The primary industry of Bal Pharma Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Yes. Bal Pharma Limited is listed on both BSE (code: 524824) and NSE (symbol: BALPHARMA).
Bal Pharma Limited can be reached at the registered office: 21 – 22 Bommasandra, Industrial Area, Bangalore South, Karnataka, India – 560099, or through the website balpharma.com.